Anyway, it makes it more interesting than the common penny pump'n'dump with just an empty shell. A nexus of scumbags plus some real scientists and biz people ... mix 'em together and what do you get?
That's a nice announcement today for the science. It's very early clinical work - Phase I safety study with some secondary efficacy targets. I think the success rate from this point to a commercial drug is generally about 5% (requiring years and $ millions).
But the approach seems sensible - I guess if it can be shown that Newell's IP safely enhances efficacy of exitsing drugs then there will be a reason for pharma companies to be interested in it, possibility of accelerated route to market.
Would be nice to see it in the hands of something with corporate credibility.
News 
Market Data 
Discover 
AI
